Lilly Reports Phase 3 TRIUMPH Data for Retatrutide, a GLP-1/GIP/Glucagon Triple AgonistEli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.
